See more : Delta Plus Group (ALDLT.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Neith Corporation (6236.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neith Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Solvbl Solutions Inc. (SOLV.CN) Income Statement Analysis – Financial Results
- Shun Ho Property Investments Limited (0219.HK) Income Statement Analysis – Financial Results
- Bio-Gene Technology Limited (BGT.AX) Income Statement Analysis – Financial Results
- Ninestar Corporation (002180.SZ) Income Statement Analysis – Financial Results
- BCE Inc. (BCE.TO) Income Statement Analysis – Financial Results
Neith Corporation (6236.TWO)
About Neith Corporation
Neith Corporation engages in the biotechnology, medical cosmetics, and preventive medicine businesses. The company offers nutritional products, including L-One, a liquid formula for maintaining eye health; EPlus, a multiple enzyme supplement; Max Care antrodia and turmeric capsules; and Max Care natto monascus capsules, as well as other nutritional products under the King One name. It also provides genetic testing services. In addition, the company offers energy and dual-purpose mattresses, energy masks, energy silicon gel necklaces, energy waistbands, energy heating stones, massage rods, and water purifiers, as well as Ganbanyoku, an energy stone spa bed. Further, it provides beauty care products, such as hydration, cell rejuvenation, GHK-CU, and restoration series skin care products, as well as home energy products, and microcontrollers and peripherals. The company was formerly known as Come True Biomedical Inc. Neith Corporation was incorporated in 1997 and is headquartered in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 39.90M | 32.06M | 31.39M | 43.74M | 33.53M |
| Cost of Revenue | 21.88M | 18.68M | 16.88M | 27.77M | 23.05M |
| Gross Profit | 18.02M | 13.37M | 14.51M | 15.97M | 10.48M |
| Gross Profit Ratio | 45.16% | 41.72% | 46.22% | 36.51% | 31.27% |
| Research & Development | 30.95M | 11.69M | 2.47M | 4.18M | 5.99M |
| General & Administrative | 27.21M | 21.13M | 13.11M | 13.73M | 23.30M |
| Selling & Marketing | 8.72M | 9.61M | 8.13M | 11.63M | 12.16M |
| SG&A | 35.92M | 30.73M | 21.23M | 25.36M | 35.46M |
| Other Expenses | 0.00 | 5.06M | 3.01M | 2.80M | -1.79M |
| Operating Expenses | 66.87M | 42.43M | 23.70M | 29.54M | 39.67M |
| Cost & Expenses | 88.76M | 61.11M | 40.58M | 57.31M | 62.71M |
| Interest Income | 1.64M | 146.00K | 74.00K | 110.00K | 283.00K |
| Interest Expense | 165.00K | 71.00K | 50.00K | 86.00K | 18.00K |
| Depreciation & Amortization | 6.26M | 5.24M | 3.35M | 2.01M | 1.86M |
| EBITDA | -33.61M | -18.49M | -2.28M | -10.40M | -9.23M |
| EBITDA Ratio | -84.23% | -58.04% | -7.73% | -15.99% | -81.48% |
| Operating Income | -48.85M | -23.84M | -5.78M | -9.00M | -29.18M |
| Operating Income Ratio | -122.43% | -74.38% | -18.41% | -20.58% | -87.03% |
| Total Other Income/Expenses | 8.82M | 5.25M | 3.84M | 2.73M | 18.98M |
| Income Before Tax | -40.03M | -23.80M | -5.35M | -10.83M | -10.20M |
| Income Before Tax Ratio | -100.33% | -74.25% | -17.05% | -24.77% | -30.42% |
| Income Tax Expense | 0.00 | -114.00K | 0.00 | 0.00 | 3.00K |
| Net Income | -40.03M | -23.69M | -5.35M | -10.83M | -17.36M |
| Net Income Ratio | -100.33% | -73.89% | -17.05% | -24.77% | -51.76% |
| EPS | -0.96 | -0.73 | -0.17 | -0.34 | -0.25 |
| EPS Diluted | -0.96 | -0.73 | -0.17 | -0.34 | -0.55 |
| Weighted Avg Shares Out | 41.65M | 32.28M | 31.65M | 31.65M | 68.08M |
| Weighted Avg Shares Out (Dil) | 41.65M | 32.28M | 31.65M | 31.65M | 31.65M |
Source: https://incomestatements.info
Category: Stock Reports